A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients with MGMT Unmethylated Glioblastoma
Details
Age
Adult
Locations
University of Colorado Hospital
Principal Investigator
Douglas Ney
Study ID
Protocol Number: 23-1257
More information available at ClinicalTrials.gov: NCT05789589
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers